Development of an Item Bank for Assessing Psychosis in Parkinson’s Disease: A Systematic Review
Objective: This study aimed to develop an item bank for assessing psychosis in Parkinson's disease (PD). Background: Psychosis is a common and debilitating symptom in…Low Vision Occupational Therapy for Parkinson’s Disease – A Pilot Study at the University of Alabama at Birmingham
Objective: Assess usefulness of low vision occupational therapy (OT) in a small cohort of Parkinson’s disease (PD) patients. Background: PD patients report vision-related symptoms more…Enhanced sensitivity to bradykinesia progression using digital health technologies in early Parkinson’s disease
Objective: To evaluate the sensitivity of digital biomarkers of bradykinesia to longitudinal progression relative to MDS-UPDRS sub-scores in early-stage Parkinson’s disease (PD). Background: It is…modulation of sodium potassium ATPase activity by norepinepherine and serotonin to find an effective cure of parkinson’s disease by introducing the novel concept of insilico drug repurposing
Objective: Parkinson's disease can cause neuropsychiatric disturbances which can range from mild to severe. This includes disorders of speech, cognition, mood, behaviour, and thought. In addition to…Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.
Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Reductions in OFF time with ND0612 for patients with Parkinson’s disease experiencing motor fluctuations: Responder-analysis from an open-label Phase 2 study
Objective: Evaluate the efficacy of subcutaneous levodopa/carbidopa infusion with investigational ND0612 in reducing OFF time in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background:…Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson’s disease
Objective: Report on the pharmacological characteristics of small molecule PROteolysis TArgeting Chimera (PROTAC) molecules designed to induce degradation of leucine rich repeat kinase 2 (LRRK2)…Deep Brain Stimulation in Parkinson’s Disease: real-world outcomes at a single centre
Objective: To describe the clinical outcomes in PD patients following DBS and analyse whether certain demographic and clinical factors are associated with poor outcomes. Background:…Correlation between rem sleep disorders and neurocognitive defects in patients with parkinson´s disease
Objective: The objective of the following study was to verify the correlation between cognitive disordersand REM sleep disorders. Background: REM sleep disorder affect a large…The effects of dopaminergic treatment on interhemispheric disinhibition and bradykinesia asymmetry in Parkinson’s disease
Objective: to investigate whether dopaminergic therapy modulates IHI and bradykinesia asymmetry in PD. Background: previous evidence demonstrated a reduced interhemispheric inhibition (IHI) in Parkinson’s disease…
- « Previous Page
- 1
- …
- 232
- 233
- 234
- 235
- 236
- …
- 436
- Next Page »